Generate Biomedicines (NASDAQ:GENB) Stock Price Down 4.8% – Should You Sell?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price was down 4.8% during mid-day trading on Friday. The company traded as low as $15.13 and last traded at $15.2250. 228,909 shares were traded during mid-day trading, a decline of 72% from the average session volume of 828,133 shares. The stock had previously closed at $15.99.

Analyst Ratings Changes

Several research firms have recently commented on GENB. Weiss Ratings initiated coverage on shares of Generate Biomedicines in a report on Tuesday, August 11th. They issued a “sell (d)” rating for the company. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Generate Biomedicines in a report on Tuesday, September 8th. Finally, Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Generate Biomedicines has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Generate Biomedicines Price Performance

The stock has a fifty day moving average price of $15.43 and a two-hundred day moving average price of $14.29. The company has a market cap of $1.95 billion and a P/E ratio of -9.55.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The company had revenue of $6.31 million during the quarter. As a group, analysts forecast that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Hedge Funds Weigh In On Generate Biomedicines

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Braidwell LP acquired a new position in Generate Biomedicines during the 2nd quarter valued at about $55,398,000. State Street Corp acquired a new stake in shares of Generate Biomedicines in the 2nd quarter worth approximately $8,883,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Generate Biomedicines in the 2nd quarter worth approximately $1,431,000. Bank of New York Mellon Corp bought a new position in shares of Generate Biomedicines in the second quarter valued at approximately $967,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Generate Biomedicines during the second quarter valued at approximately $530,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and machine learning to discover and design protein-based medicines. Its technology is intended to model relationships among protein sequences, structures and biological functions, helping researchers create therapeutic proteins with desired characteristics.

The company’s research activities are focused on developing novel biologic medicines for areas of significant unmet medical need, including oncology, immunology, infectious diseases and rare diseases.